Results 261 to 270 of about 59,490 (287)

Bioengineering virus‐like particles as vaccines

Biotechnology and Bioengineering, 2013
ABSTRACTVirus‐like particle (VLP) technology seeks to harness the optimally tuned immunostimulatory properties of natural viruses while omitting the infectious trait. VLPs that assemble from a single protein have been shown to be safe and highly efficacious in humans, and highly profitable.
Lua, Linda H. L., Connors, Natalie K., Sainsbury, Frank, Chuan, Yap P., Wibowo, Nani, Middelberg, Anton P. J.   +5 more
openaire   +3 more sources

Virus-Like Particles as Particulate Vaccines

Current HIV Research, 2010
Particulate structures hold great promise for the development of effective and affordable recombinant prophylactic as well as therapeutic vaccines. Different types of particulate structures, including virus-like particles (VLPs) and virosomes, have been developed depending on the nature of the viral pathogen to be targeted and the type of immune ...
Luigi, Buonaguro, Maria L, Tornesello, Franco M, Buonaguro   +2 more
openaire   +2 more sources

Transcutaneous vaccination with virus-like particles

Vaccine, 2006
Virus-like particles (VLP) are inert, empty capsids of viruses, which contain no DNA/RNA from the virus itself. However they retain the structure of a virus and they can be engineered to have antigens attached. We have constructed VLP, derived from Rabbit hemorrhagic disease virus, and shown they are highly immunogenic.
Young, Sarah, Wilson, Michelle, Wilson, Sarah, Beagley, Kenneth, Ward, Vernon, Baird, Margaret   +5 more
openaire   +3 more sources

Virus-like particles: potential veterinary vaccine immunogens

Research in Veterinary Science, 2012
Virus-like particle (VLP) composed of outer shell but no genome of virus mimics the natural configuration of authentic virion and has no characteristics of self-replication. A close resemblance to native viruses in molecular scaffolds and an absence of genomes make VLPs effectively elicit both humoral and cell-mediated immune responses even with no ...
Fuxiao, Liu, Shengqiang, Ge, Lin, Li, Xiaodong, Wu, Zengshan, Liu, Zhiliang, Wang   +5 more
openaire   +2 more sources

Virus-like particles as HIV-1 vaccines

Reviews in Medical Virology, 2005
Traditional successful antiviral vaccines have relied mostly on live-attenuated viruses. Live-attenuated HIV vaccine candidates are not ideal as they pose risks of reversion, recombination or mutations. Other current HIV vaccine candidates have difficulties generating broadly effective neutralising antibodies and cytotoxic T cell immune responses to ...
Linh X, Doan, Min, Li, Changyi, Chen, Qizhi, Yao   +3 more
openaire   +2 more sources

Virus-Like Particle Vaccines for Mucosal Immunization

1997
Viruses which infect the gastrointestinal tract are well suited for examining the immune response(s) to oral delivery of antigen and exploring the advantages and pitfalls of oral vaccines. We have used recombinant DNA techniques to produce nonreplicating self-assembled virus-like particles (VLPs) from two gastrointestinal viruses, rotavirus and Norwalk
M K, Estes, J M, Ball, S E, Crawford, C, O'Neal, A A, Opekun, D Y, Graham, M E, Conner   +6 more
openaire   +2 more sources

Virus-like particles in picornavirus vaccine development

Applied Microbiology and Biotechnology, 2014
Virus-like particles (VLP), which are similar to natural virus particles but do not contain viral genes, have brought about significant breakthroughs in many research fields because of their unique advantages. The ordered repeating epitopes of VLP can induce immunity responses similar to those prompted by natural viral infection; thus, VLP vaccines are
Hu, Dong, Hui-Chen, Guo, Shi-Qi, Sun
openaire   +2 more sources

Virus-like Particle-based Vaccines: GARDASIL®

2022
Papillomaviruses are widely distributed in Nature among mammals where infection of humans, cattle, dogs, rabbits, monkeys, and other species is typically asymptomatic, but may cause small benign tumors known as papillomas or warts, or even carry a risk of becoming cancerous.
M. Kosinski, P. Dephillips, W. Manger, D. Abraham   +3 more
openaire   +1 more source